Methods and systems for monitoring respiratory data

Information

  • Patent Grant
  • 8628480
  • Patent Number
    8,628,480
  • Date Filed
    Wednesday, December 22, 2010
    14 years ago
  • Date Issued
    Tuesday, January 14, 2014
    11 years ago
  • Inventors
  • Original Assignees
  • Examiners
    • Kahelin; Michael
    • Toth; Karen
    Agents
    • Sterne, Kessler, Goldstein & Fox P.L.L.C.
Abstract
This invention provides methods and systems for non-invasively determining the presence (and amount) or absence of dynamic hyperinflation in a subject. The invention is based on a novel combination of respiratory parameters that can be measured in a way that is non-invasive and unobtrusive to the subject. Dynamic hyperinflation is often a significant factor in the quality of life of patients suffering from a variety of obstructive pulmonary diseases, and this invention permits simple, routine tracking and management of dynamic hyperinflation in affected patients.
Description
1. FIELD OF THE INVENTION

The present invention relates to determination of pulmonary parameters of individuals, especially pulmonary parameters of patients with obstructive pulmonary diseases. More particularly, this invention provides systems and methods that measure dynamic hyperinflation using methods that require little if any patient attention.


2. BACKGROUND OF THE INVENTION

Chronic obstructive pulmonary disease (COPD) and other diseases with a similar physiological defects (e.g., acute and chronic asthma) are of considerable clinical interest since they are important worldwide causes of morbidity and mortality. Cardinal symptoms of these diseases include sensations of dyspnea or breathlessness as well as other respiratory discomforts. These occur on exertion, and in advanced disease also at rest. Briefly, these symptoms are due to progressive loss of lung volume available for active breathing as the lung becomes filled with more and more air trapped (“hyperinflation”) behind airways that have increasing expiratory flow limitations. The airway expiratory flow limitations result from the pathology underlying these diseases that, for example, causes blockages within airways (e.g., by increased mucus) or partial airway collapse (e.g., by decreased tethering due to parenchymal destruction). The increase in lung volume changes the pressure-volume relationship of the chest-wall, reducing the efficiency of the respiratory musculature.


Pathologically, COPD is a heterogeneous disorder characterized by expiratory flow limitations usually due to narrow, easily collapsed airways. When arising from emphysema or chronic bronchitis, parenchymal and vascular destruction reduces lung recoil and airway tethering leading to expiratory collapse of small and large airways. Acute and chronic asthma, along with chronic bronchitis, can also cause expiratory flow limitation by airway narrowing due to bronchial hypertrophy, bronchial spasm, and increased viscid secretions into the bronchi. Pulmonary diseases characterized by prominent expiratory air flow limitations are generically referred to herein as “obstructive pulmonary diseases” (OPD).


It is common during the course of these diseases that periods of acutely increased hyperinflation (“dynamic hyperinflation”) are superimposed on the chronic underlying and often slowly progressive hyperinflation. Dynamic hyperinflation (abbreviated as “DH”) is associated with periods of increased drive to breathe which can be due to exercise (“exercise dyspnea”), excitement, pulmonary infections, waking in the morning, and numerous other factors. The additional hyperinflation caused by DH can even further decrease lung capacity available for active breathing, and therefore can be a substantial factor in the experience of patients with COPD and similar diseases, negatively impacting their functional capacity and quality of life.


Thus, it is clinically advantageous to track and treat episodes of DH to the extent possible. In the prior art, DH has usually been tracked by serial measurements of inspiratory capacity (abbreviated herein as “IC”) requiring a patient to perform a specific breathing maneuver at rest while, for example, breathing into a spirometer or breathing while inside a calibrated pneumo-tachographic chamber. The specific maneuver requires that the patient must, first, repeatedly inspire and expire in a relaxed manner, and then must inspire maximally and resume normal breathing. The IC is difference between the last inspiratory volume and the last tidal expiratory volume. Preferably, this maneuver is repeated until two or more consistent IC values are obtained.


This requirements of this measurement technique can distort IC measurements, and thus confound identification and measurement of DH also. A patient must interrupt whatever they were doing and then consciously attend to and perform a specific breathing sequence while using instrumentation that is at best cumbersome. The large inspiration required by IC measurement can be unpleasant, and may actually trigger a period of hyperinflation. Performance of the IC maneuver is especially intrusive during exercise, and measurements of DH precipitated by exercise (“exercise dyspnea”) are likely to be more confounded than are measurement of other forms of DH.


The prior art lacks systems and methods for measuring DH that require little or no attention by a patient. Such methods and system would be useful for, e.g., assessing and managing COPD and other lung diseases.


A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference for all purposes. Further, none of these references, regardless of how characterized above, is admitted as prior to the invention of the subject matter claimed herein.


3. SUMMARY OF THE INVENTION

The objects of this invention include methods and systems that assess dynamic hyperinflation (“DH”) in a patient unobtrusively, that is with little or no attention by the patient, and also preferably non-invasively, that is permitting the patient to perform normal daily activities. Tracking and managing DH using this invention can be useful in improving the quality of life of patients with obstructive pulmonary diseases (“OPD”), because DH can be a substantial factor in their disease experience. OPD patients include patients with obstructive pulmonary diseases, e.g., COPD, chronic bronchitis, emphysema, chronic or acute asthma, and other diseases with similar physiological effects.


This invention is based on the inventor's discovery that the presence or absence of DH and its amount (e.g., the volume of dynamically retained air) can be assessed by a novel combination of respiratory parameters. In particular, patterns of changes in the median rib cage contribution to tidal volume (M % RC when measured in percent) and the median absolute value of changes in end-expiratory lung volume (MqdEELV) can reliably detect DH. During periods of increased respiratory demand, e.g., during exercise, these parameters often increase together in normal patients who do not have DH. In other normal patients, one of these parameters may change while the other does not change, or neither of these parameters may change. In contrast, OPD patients experiencing DH during periods of increased respiratory demand demonstrate a different and unique pattern in which MqdEELV increases while M % RC decreases. These different patterns of changes of MqdEELV and M % RC reliably discriminate patients who experience DH from those who do not. As used here, a parameter “changes” (or “increases” or “decreases”) if its values, or if an average, or median, or mode, or other statistical measure of its values, observed in two conditions differ to a statistically meaningful degree.


This invention provides methods and programmed computer systems that implement this discovery. These methods and systems receive respiratory data sufficient to determine MqdEELV and M % RC, process this data, and output assessments of the presence or absence of DH and optionally of its amount. Various preferred embodiments of this inventor are more or less specifically directed to different patient measurement environments, e.g., hospital environments, clinical environments, ambulatory environments, laboratory environments, and the like. Specifically, the various embodiments are adapted to accept respiratory data from the different respiratory sensors found in these different environments, and are implemented on the various types of computers also found in these different environments, from computers with limited portability to portable computers that can be carried by a patient.


One preferred embodiment is directed to ambulatory patients. As used herein “ambulatory environment” (or “ambulatory”), is taken to means an environment that permits patients to engage their normal daily activities in a substantially unconstrained manner. In this embodiment, respiratory data is measured using sensors configured on and/or carried by a comfortable wearable item. Preferred respiratory sensors measure sizes of the patient's torso at one or more levels, e.g., at a rib cage level and/or and abdominal level, using plethysmographic technologies, particularly inductive plethysmographic technologies. Data is processed either by portable processing devices that can be carried by the patient or by remote computer systems at least to extract tidal volume (VT) from sensor data and then to determine MqdEELV and M % RC from VT data. DH is then assessed in dependence one the latter two parameters. Processed and/or raw respiratory data is preferably transmitted from local devices to remote systems using means that permit a patient to carry out their normal activities with little or no significant constraint. For example, data can be transmitted wirelessly, or physically transferred on computer readable media.


Specifically, “plethysmography” and its derivative words, as used herein, refer to an externally-determined (non-invasive) measurement of a size of a body part. Also, “inductive plethysmography”, as used herein, is a plethysmographic measurement based on determination of an inductance or a mutual inductance of conductive elements arranged on the body part. A “plethysmographic signal” is a signal generated by plethysmography, and usually by inductive plethysmography. The part of the body measured by plethysmography may include, singly or in combination, one or more portions of the chest, abdomen, neck, arm, or the like.


The present invention also includes computer readable mediums, both for long term storage and for portable storage, which are configured with encoded instructions for causing a processor to perform the methods of this invention and/or with raw or processed data used by these methods.


Specific embodiments of this invention will be appreciated from the following detailed descriptions, appended claims, and attached figures.





4. BRIEF DESCRIPTION OF THE DRAWINGS

The present invention may be understood more fully by reference to the following detailed description of preferred embodiments of the present invention, illustrative examples of specific embodiments of the invention, and the appended figures in which:


FIGS. 1A1-1A4 illustrate aspects or respiratory anatomy;



FIGS. 1B-D illustrate aspects of respiratory function;



FIG. 2 illustrates calibrated respiratory data;



FIG. 3 illustrates the measurement of EELV in this invention;



FIG. 4 illustrates respiratory data from a normal patient;



FIG. 5 illustrates respiratory data from a patient with OPD;



FIG. 6 illustrates ambulatory monitoring devices; and



FIG. 7 illustrates methods of this invention.





5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the following, and in the application as a whole, headings are used for clarity and convenience only and without any intent to thereby alter or narrow the scope of the invention.


Dynamic Hyperinflation


This subsection provides brief descriptions of known aspects of pulmonary functioning that are useful for describing and supporting the present invention, in particular, aspects of respiratory mechanics and of respiratory volumes.


FIGS. 1A1-4 schematically illustrate relevant aspects of respiratory anatomy and mechanics. FIGS. 1A1 and 1A2 illustrate a side view and a cross section of a rib cage in inspiration. FIGS. 1A3 and 1A4 illustrate a side view and a cross section of a rib cage in expiration. Respiratory muscles acting directly on the rib cage are not illustrated; only diaphragm 23 is illustrated. Referring first to FIGS. 1A1 and 1A2, the respiratory muscles during inspiration act to lift and expand rib cage to position 11 and to lower the diaphragm to position 15. Referring now to FIGS. 1A3 and 1A4, during expiration, the respiratory muscles relax, and tissue elasticity and passive recoil allow the rib cage to contract to position 19 and the diaphragm to rise to position 21. Accordingly, measures of rib cage size (RC) increase during inspiration and decrease during expiration. This can be appreciated from the relation of the rib cage to equal length arrows 13 (FIGS. 1A1 and 1A3). Similarly, measures of abdomen (AB) size increase during inspiration and decrease during expiration. This can also be appreciated from the relation of the abdomen to equal length arrows 17 (FIGS. 1A2 and 1A4).


RC and AB size measurements (or either alone) can be linearly combined according to a two compartment breathing model in order to determine the various lung volumes, e.g., tidal volume, to within 5-10% of these volumes determined using a spirometer (a current measurement standard). Furthermore, comparing measurements of changes in rib cage and abdominal sizes to determined lung volumes, it can be determined how much of an individuals is due to rib cage motion and how much is due to diaphragmatic motion.


It is also known that, when inspirations and expirations occur at chest volumes in the central parts of their volume ranges, approximately midway from their minima to their maxima, a given change in lung volume requires a linear or proportionate amount of respiratory muscle effort (working against the elasticity of chest wall and lung). That is, in these volume ranges, the lung compliance is approximately constant so that minute ventilation (VE) increases approximately linearly and proportionately with respiratory muscle work. However, it can be appreciated from FIGS. 1A1 and 1A2 that when breathing occurs with chest and lung volumes in the upper part of their ranges, near their maxima, each breath requires that an already expanded rib cage 11 must be further expanded and an already lowered diaphragm 15 must be further lowered. This is mechanically and elastically disadvantageous; and each breath requires a non-linearly and disproportionately greater amount of respiratory muscle effort. Because of this decreasing lung compliance, greater and greater efforts and required to increase VE.


Next, FIGS. 1B-C illustrate schematically (and not to scale) relevant aspects of functional lung volumes. Referring first to FIG. 1B, total lung capacity (TLC) is the total volume of air in the lung; residual volume (RV) is the total volume of air remaining in the lung after a maximum expiratory effort; and function residual capacity (FRC) is the total volume of air remaining in the lung after a tidal expiration. (Alternately, TLC is often defined to include dead volume where there is no significant air exchange.) Measurement of these volumes commonly requires cumbersome techniques, for example, body plethysmography or gas dilution measurements.


The remaining lung volumes are more easily measured during routine breathing. Vital capacity (VC) is the expiratory volume from a maximal inspiration down to a maximal expiration. Normal breathing defines tidal end inspiratory lung volume (EILV) and tidal end expiratory lung volume (EELV), and the difference of these volumes defines tidal volume (VT). Inspiratory capacity (IC), inspiratory reserve volume (IRV), and expiratory reserve volume can then be determined from VC and VT (either resting or exercise) as illustrated. In particular, IC is the inspiratory volume from a regular expiration up to a maximal inspiration, and will vary proportionately with the EELV.



FIG. 1C illustrates a normal subject's response to increased respiratory demand, such as occurs during exercise. The principal response is to increase VT; the secondary response is to increase respiratory frequency, but usually only at high levels of respiratory demand. Because normal subjects have substantial IC and IRV, VT is easily increased by simply taking deeper inspirations without changing the EELV. Healthy subjects may also demonstrate a decreasing EELV as permitted by their VC and ERV. These inspiratory volume increases (and also expiratory volume increases) occur in the mid-range of TLC, e.g., between 20% and 60% of TLC. In this range, the respiratory system's compliance is largely constant, and increased respiratory effort leads to substantially linear and proportional increases in VT and VE.


COPD, and other lung diseases leading to similar physiological defects, can dramatically compromise the normal respiratory response to increased respiratory demand. FIG. 1D illustrates a patient with advanced COPD. This patent's ventilatory reserve volumes are dramatically decreased by air flow limitations, incomplete expiratory lung, and static trapping of air not expired in lung segments with little of no ventilation in such patients leads. At rest (i.e. for ventilation near 10 L/min in FIG. 1D), approximately 70% of the lung is no longer available for active respiration and gas exchange. Only approximately 20% of TLC remains available as ventilatory reserve volumes, VC, IC, and ERV, which can be used to increase VT when needed. Also, as the active and ventilated lung volumes are displaced upward and closer to total lung capacity, respiratory compliance decreases. Increases in VE and VT then require greater and greater respiratory effort; and breathing becomes more and more tiring. OPD also increases to work of breathing also by increasing airway resistance. The patient illustrated in FIG. 1D therefore loses the normal subject's capability to substantially increase VE in response to respiratory demand (i.e., exercise).


In addition to being chronic, air trapping can also be acutely exacerbated and increased by various precipitating factors, e.g., a patient's attempts to increase VE as might occur during exercise. This can be seen by comparing the course of EELV and IC in FIGS. 1C and 1D. In a normal subject, FIG. 1C illustrates that EELV and IC are not substantially altered when VE increases. Thus, ventilatory residual volumes, or the lung volumes available for increased ventilation, are not compromised and remain available for increasing VT. However, FIG. 1D illustrates that, in an OPD patient, EELV can further increase and IC can further decrease during even modest increases in VE. Here, ventilatory residual volumes are compromised and are not available for increasing VT. In fact, it can be seen that the possible increase in VT is quite limited. However, it is also apparent from FIG. 1D that, if EELV and IC were substantially constant as VE increased, the patient's ventilatory reserve volumes, although already quite limited, are at least not further compromised and can be fully used to increase VT and thus VE. This additional effect of OPD, though to be caused by dynamically increased air trapping, is known as “dynamic hyperinflation” (DH). DH is dynamic because after precipitating factors cease, lung volumes return to their previous values.


The occurrence and extent of DH is variable. Determinants of DH include: baseline lung hyperinflation, expiratory flow limitation, ventilatory demand, and breathing pattern. The occurrence of DH is also variable. It be precipitated by different causes in different patients, for example, by exercise, by lung infection, by cold, by allergens and so forth. Although air trapping can range from 0.1 L or less, to 0.3 L, and to ≧1.0 L, absolute volumes must be compared to a patient's remaining lung function. Only 0.1-0.2 L of additional air-trapping can significantly compromise an individual already breathing with virtually no ventilatory reserve.


Thus DH acts like a further worsening of a patient's underlying disease because it further decreasing reserve volumes just when the patient needs them in order to increase ventilation. In these situations, notably during exercise, OPD patients can experiences increased sensations of dyspnea, breathlessness, and other discomforts. Therefore, tracking and managing DH in OPD patients can help preserve their functional capacity and quality of life.


Determination of Dynamic Hyperinflation


This subsection describes this invention's novel techniques and methods for non-invasively and unobtrusively determining dynamic hyperinflation. These are based on the discovery that the presence or absence of DH and an indication of its amount (volume) can be reliably determined by a finding specific pattern of joint changes in two specific respiratory parameters occurring during exercise or after other precipitating factor. On the other hand, DH cannot be reliably determined from only one of these parameters in isolation from the other.


The two significant parameters are known as “median % rib cage” (“M % RC”) and “median cumulative change in end expiratory lung volume” (“MqdEELV”). These parameters and their measurement are now described. First, M % RC is a parameter available for each breath and measures the relative portion of a breath that is due to expansion and contraction of the rib cage. The remaining portion of the breath is due, as explained above, to contraction and relaxation of the diaphragm. FIG. 2 illustrates exemplary data. Graph 45 represents the tidal volumes (VT) a series of breaths, each breath has a rising inspiratory portion and falling expiratory portion. Graph 47 represents concurrent relative changes in rib cage volumes, and graph 49 concurrent relative changes in abdomen volumes. For each breath, the % RC (percent RC) is the ratio of the amplitude in graph 47 to the corresponding amplitude in graph 45.


M % RC can be determined from respiratory measurements including tidal volume, or its equivalent, and rib cage size, or its equivalent, and is a weighted and/or normalized ratio of changes in rib cage size to the tidal volume. In preferred embodiments, respiratory data includes non-invasive, unobtrusive, moment-by-moment measurements of a rib cage size, known as RC, and an abdominal size, known as AB. Then, suitable weights α and β can be chosen so that tidal volume can be reliably determined from the formula:

VT=α*AB+β*RC  (1)


The % RC (percent RC) is then:










%





RC

=


β
*
RC


V
T






(
2
)








M % RC is a statistical median of % RC determined for breaths occurring during sequential 30 sec., or 1 min, or 2 min., or other periods. In other embodiments, VT can be alternately determined from a linear or non-linear function of AB and RC, and an alternate statistical measure, e.g., an average, can be used to represent values of % RC during sequential periods.


Next, finding MqdEELV requires prior determination of changes in EELV. Patterns of change in EELV are sufficient; the methods of this invention do not require absolute values of EELV. In preferred embodiments, changes in EELV are determined breath-by-breath by comparing the inspiratory volume of each breath to its expiratory volume. FIG. 3 illustrates a preferred method. Graph 31 schematically (not to scale) represents VT and includes four illustrative breaths, breaths 36, 40 and 42 being specifically identified. Breath 36 has inspiratory volume 35, which is measured from the end expiration of the previous breath to peak inspiration of breath 36, and expiratory volume 37, which is measured from peak inspiration of breath 36 to end expiration of breath 36. Since inspiratory volume 35 is greater than expiratory volume 37, breath 36 has caused EELV to increase by the difference in these volumes. EELV is represented by graph 33, and this graph depicts the EELV increase due to breath 36 by step 39. Breath 40 is similar: inspiratory volume 39 is greater than expiratory volume 41; and graph 33 represents this EELV increase by step 43.


Accordingly, graph 31 of EELV steps up by amount 39 at breath 36, by amount 43 at breath 40, and by a further amount at breath 42. Over the course of these three breaths, EELV cumulatively stepped up by amount 45. In actual respiratory data, EELV can both increase and decrease, and the cumulative change in EELV for a period of time cumulates all increases and decreases during that period. Finally, MqdEELV is the statistical median of the absolute value of a number of cumulative changes in EELV determinations made during sequential 30 sec., or 1 min, or 2 min., or other periods. In other embodiments, changes in MqdEELV can be determined by linear or non-linear combinations of inspiratory and expiratory volumes from two or more breaths; EELV changes can be cumulated by running averages and the like; and alternate statistical means, e.g., an average, can be used to characterize changes in EELV during sequential time periods.


Once these parameters are determined, the methods of this invention identify a patient who dynamically traps air in response to an inciting event (e.g., exercise, infection, etc.) because of an increasing MqdEELV together with a decreasing M % RC. Such patients are referred to herein as “+DH”. In patients who do not dynamically trap air, referred to as −DH, MqdEELV and M % RC do not exhibit this pattern. In such patients, either MqdEELV decreases, or both MqdEELV and M % RC increase together.



FIGS. 4 and 5 illustrate these two patterns. In these figures, median values are determined for a time equal to approximately one and one-half time the vertical grid line spacing. FIG. 4 illustrates a healthy, −DH, subject who exhibits a normal pattern of joint changes in MqdEELV and M % RC during exercise. This patient has a significant exercise capability as evidence by a heart rate increase from approximately 70 beats per minute (bpm) to over 170 bpm. During the exercise period, the MqdEELV is stable, while the M % RC increases a small amount, from approximately 40% to approximately 50%. This pattern reflects a normal exercise response in which minute ventilation is increased by increasing tidal volume using rib cage muscles and the diaphragm in approximately equal proportions. No air trapping is evident. Another common normal pattern is a relatively small decrease in MqdEELV, because of somewhat large expirations, together with a relatively small increase in M % RC, because of relatively increased use of rib cage muscles. Also normals can exhibit a small increase in MqdEELV with changes in M % RC that are either not significant or are decreases.



FIG. 5 illustrates a subject with an obstructive pulmonary disease (here, COPD). First, this subject's exercise tolerance is decreased due to limitation in their ability to increase their minute ventilation. This is evidenced here by the only approximately 20 bpm increase in heart rate from an already elevated resting rate. Next, the MqdEELV significantly increases by approximately 140 ml; and the M % RC even more significantly decreases, falling from an approximately normal level above 40% to a much depressed level below 16%. These changes are consistent with dynamic air trapping. Increasing MqdEELV reflects increased air trapping and decreased volumes available for ventilation. A significantly decreasing M % RC reflects further physiologically significant dynamic air trapping in an already hyperinflated lung. Additional trapped air in a hyperinflated lung both limits rib cage contraction and further decreases an already abnormally decreased lung compliance. Both factors reduce the mechanical efficiency of the rib cage muscles, and the decreasing M % RC indicates that these muscles are now incapable of the extra effort to maintain ventilation.


Table 1 further illustrates how the novel pattern of an increasing MqdEELV and a decreasing M % RC separates +DH from −DH patients.














TABLE 1








Patients






without
Patients




Parameter
DH on
with DH on
Difference



(base line -
exercise
exercise
(+DH



end exercise)
(−DH)
(+DH)
minus −DH)





















MqdEELV
−81.36
66.50
−147.86



M % RC
1.09
−12.50
13.59











This table summarizes data from a study of fifteen patients, some with DH confirmed by standard measurement techniques and some without DH also as confirmed by standard techniques. Changes in MqdEELV and M % RC were measured for each patient. It is readily apparent that +DH patients exhibit the pattern of increasing MqdEELV and decreasing M % RC, while −DH patients exhibit other patterns.


In further preferred embodiments, values of MqdEELV and M % RC are combined using a model developed according to statistical pattern recognition techniques for particular patient populations into a discriminant variables that clearly distinguish +DH from −DH in each population. Further, these discriminant variables can be chosen so that amount of DH (in ml) correlates with the value of the variables so that both presence and amount of DH can be determined. Other embodiments use models developed by other than statistical techniques and can incorporate further variables (such as intensity of exercise or of other inciting cause).


Preferred Systems and Methods of this Invention


Preferred systems and methods suitable for the practice of this invention are described next.


This invention can be practiced in many different patient monitoring environments as long as respiratory data is available from which at least moment-by-moment VT data and rib cage contribution to VT can be determined. For example, this invention can be practiced in hospital, clinic, or laboratory environments and use data from respiratory sensors available in these environments. Such sensors include, e.g., spirometeric measuring arrangements, body plethysmography, and the like and are often less portable, can limit or prevent patient motion, but offer greater measurement accuracies. These environments also often provide, e.g., exercise treadmills and the like which can provide graded stimuli to precipitate DH. This invention can also be practiced in a patient's day-to-day environment while the patient is performing day-to-day activities (referred to herein as “ambulatory environments”). In such embodiments, this invention usually processes data from respiratory sensors that are portable, light weight, non-invasive, and is arranged and configured so as not to limit patient motion or activity. Although practice in ambulatory environments is preferred and further described herein, this should not be understood to limit the broad applicability of this invention.


For ambulatory environments, respiratory sensors preferably respond to indicia of body sizes, such as lengths, circumferences, diameters, or geometrically similar measures of at least the rib cage and the abdominal and of their moment-by-moment changes during respiration. As already described, from rib cage and abdominal size measurements, moment-by-moment VT and rib cage contribution to VT can be determined. Such sensors (referred as “size sensors”) at one or more additional torso or limb cross-sections can provide additional data responsive to cardiac or aortic pulsations, venous or arterial pulsations, and the like.


Size sensors can be based on diverse technologies, including magnetometers; strain gauges using magnetic, mechanical or optical means; optical techniques including interferometry; electrical impedance; surface electrical or magnetic activity; body plethysmography, ultrasonic and doppler measurements of body wall motions or body diameters; and so forth. Preferred size sensors are based on inductive plethysmographic (IP) technology, which is responsive to anatomic sizes by measuring the self-inductance of one or more conductive elements (metallic or non-metallic) arranged on the anatomic portion to be measured. Briefly, IP sensor self-inductance varies as its size changes in response to an underlying body part; the varying self-inductance is sensed by variable frequency oscillator/demodulator modules; these modules output digital signals responsive to oscillator frequencies and ultimately to sensor size. Respiratory measurements obtained by IP technology are routinely within 5-7% (or 10 s of ml) of measurements obtained by spirometry, a current clinical standard.


IP technology has been described in patent applications and issued patents assigned to the assignee of the present application including: U.S. Pat. Nos. 6,551,252; 6,413,225; 6,047,203; 6,341,504; 5,331,968; 5,301,678; 4,807,640; 4,373,534; and 4,834,209, and also U.S. application Ser. No. 10/822,260. All patents and published U.S. application cited herein are incorporated herein by reference in their entireties for all purposes.


Additional sensors are advantageous in order to record the context when DH is found to occur. For example, accelerometers mechanically coupled to a monitored patient can provide data reflecting activity level and posture; sensors for blood oxygen saturation can provide data reflecting any de-saturation accompanying DH. Other sensors can provide data reflecting skin conductance, electrical impedances, temperature, sensors; ultrasound, and the like.


Respiratory and other sensor data is conveyed from the monitored patient to processing devices, or computers, or computer systems for processing and analysis by programmed implementations of this invention's methods. If patients are constrained, sensors can be linked directly to processing systems, e.g., by cable. If patients are unconstrained as in ambulatory environments, it is preferable that a portable processing device or computer (referred to as a “portable data unit” or “PDU”) carried by a subject receive sensor data. In certain embodiments, the PDU also temporarily stores and/or transmits it to remote computers for analysis. In an ambulatory environment, data transmission should not limit a subject and can be by, e.g., wireless transmission, or physical transport of computer readable media, or the like. In other embodiments, the PDU also perform the methods of this invention.


For ambulatory applications, respiratory and other sensors are preferably configured unobtrusively and comfortably on the patient so as not to substantially limit motion or activity. For example, sensors can be configured into one or more wearable items, e.g., shirts, jackets, bands, patches, and the like. FIGS. 6A-C illustrate exemplary ambulatory monitoring systems having sensors configured into wearable items.


The subject of FIG. 6A is actively exercising unconstrained by concurrent monitoring with a single chest band 71 and PDU 73 configured as a wrist watch. The single band preferably incorporates a size sensor sensitive to respiration and can also incorporate accelerometers, ECG sensors, temperature sensors, and so forth. FIG. 6B illustrates shirt-like garment 75 having several types of sensors, including two (or more) size sensors 77 preferably sensitive to rib cage (RC) and abdomen (AB) sizes, two ECG leads, and optionally additional sensors (not illustrated). Here, PDU 81 can displays data and accept user input. FIG. 6C illustrates a body-suit-like garment 83 equipped with a more extensive array of size sensors 85 for measuring respiration rate and volume, venous and arterial pulsations, cardiac pulsations, individual lung function, and the like. Here, PDU 87 is attached to the garment and retrieves and wirelessly transmits sensor data to storage and analysis systems. Monitoring garments and systems are available from VivoMetrics, Inc., Ventura, Calif.


Sensor data can be partially or wholly processed by a processing device in the PDU. In certain embodiments, processed and/or raw data is also transmitted to a remote computer system. FIG. 6D illustrates an exemplary analysis system including PC-type or workstation-type computer 91 with an attached monitor for viewing unprocessed and processing sensor data. Data is 89 conveyed to system 91 by, e.g., wireless connection, physical transfer, or wired connection. Local or remote online computer readable memory 93 and removable computer readable memories 95 (e.g., optical ROM) holds unprocessed and/or processed data and/or programs, and the like.


The methods of this invention are generally performed on a computer or other processing device. Accordingly, these methods are programmed in a convenient computer language, such as assembly language, C, or C++, compiled into an executable form and stored on a computer readable medium for loading into a program memory of a computer or the configuration registers of a programmable device, or the like. FIG. 7 illustrates an exemplary implementation of these methods. These illustrated steps can be repeated on demand, or intermittently, or periodically to make multiple DH assessments.


After beginning at step 101, next step 103 measures and/or retrieves and/or inputs current monitoring data and optionally comparative measurement data. DH is additional hyperinflation acutely superimposed on chronic, baseline (BL) hyperinflation. To assess the degree or severity of a current bout of DH, it is therefore advantageous to have available comparative data that measures of the BL hyperinflation. Comparative data can include values or combinations of MqdEELV and M % RC during past bouts of DH, statistical distributions of multiple observations of MqdEELV and M % RC; the values of MqdEELV and M % RC resulting from specific precipitation factors, the amount of air retained, and the like.


Should the input data include RC and AB size measurements, step 105 next extracts tidal volume (VT) and the rib cage contribution to tidal volume from these raw methods accordingly to methods known for IP. Step 107 perform implementations of the previously methods for finding M % RC and MqdEELV. Finally, step 109 assesses DH, its presence or absence and optionally its amount or volume, from the determined M % RC and MqdEELV parameters accordingly to the discrimination already described. The severity of DH can be estimated from the increases in lung volume or other measured in view of past values provided in the comparative data.


Validation step 111 is optional but preferred to insure and/or improve the reliability of DH assessments. In one simple alternative, single measurements the M % RC and MqdEELV parameters are made from sufficiently long measurement periods, e.g., at least 30 sec, or at least 60 sec, or at least 120 sec. long or longer. In another alternative, DH assessment uses M % RC and MqdEELV values that are determined by statistically combining two or more independent measurements of these parameters. In a further alternative, a final DH assessment is determined by statistically combining values from two or more independent episodes of DH precipitated by separate occurrences of a precipitating factor, e.g., exercise. Values can be combined using modes, medians, averages, and the like in order to statistically improve accuracies and limit errors. Prior DH episodes can be provided in the comparative data.


The invention described and claimed herein is not to be limited in scope by the preferred embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.


A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference for all purposes. Further, none of these references, regardless of how characterized above, is admitted as prior to the invention of the subject matter claimed herein.

Claims
  • 1. A computer-implemented method suitable for use during exercise activities for assessing respiratory data in a monitored subject, the method comprising: monitoring respiration of the subject with a physiological monitoring system, wherein the physiological monitoring system comprises a magnetometer for collecting respiratory data;using a processor to determine a tidal volume of the subject based on the respiratory data;using the processor to determine a first parameter indicative of the relative contribution of expansion and contraction of the subject's rib cage to the subject's tidal volume;using the processor to determine a second parameter indicative of median cumulative changes in end-expiratory lung volume; andassessing respiratory data in the subject in dependence on the first and second parameters.
  • 2. The computer-implemented method of claim 1, wherein the monitoring respiration of the subject is performed during a subject monitoring period, and wherein the first and second parameters are determined from received respiratory data from the same subject monitoring period.
  • 3. The computer-implemented method of claim 2, wherein the respiratory data of the subject monitoring period is compared with a previous subject monitoring period.
  • 4. The computer-implemented method of claim 1, wherein using a processor to determine the second parameter comprises: determining a breath-by-breath change in expiratory lung volume;determining a cumulative change in expiratory lung volume in dependence on a plurality of consecutive breath-by-breath changes in expiratory lung volume; anddetermining the median cumulative changes in end-expiratory lung volume parameter in dependence on the absolute values of a plurality of cumulative changes in expiratory lung volumes.
  • 5. The computer-implemented method of claim 4, wherein determination of the breath-by-breath change in expiratory lung volume comprises subtracting the expiratory volume of the breath from the inspiratory volume of the breath.
  • 6. The computer-implemented method of claim 1, further comprising gathering data relating to a rib cage size and an abdomen size of the subject, determining a lung volume parameter by linearly combining the rib cage size and the abdomen size; anddetermining tidal volume of the subject in dependence on a difference of the lung volume parameter at the end of inspiration and the lung volume parameter at the end of a following expiration.
  • 7. The computer-implemented method of claim 1, wherein determining the first parameter comprises dividing respiratory volume during expansion of the subject's rib cage by the subject's tidal volume.
  • 8. The computer-implemented method of claim 1, wherein the respiratory data comprises a rib cage size of the subject, and wherein respiratory volumes during rib cage expansion and contraction are determined in dependence on the rib cage size.
  • 9. The method of claim 1, wherein the subject performs normal daily activities during the monitoring period.
  • 10. A computer for assessing respiratory data in a subject monitored during exercise with a physiological monitoring system, wherein the physiological monitoring system comprises a magnetometer for collecting respiratory data, the computer comprising: a processor; anda computer-readable memory operatively coupled to the processor, wherein the processor is configured to:determine a tidal volume of the subject based on the respiratory data;determine a first parameter indicative of the relative contribution of expansion and contraction of the subject's rib cage to the subject's tidal volume;determine a second parameter indicative of median cumulative changes in end-expiratory lung volume; andassess respiratory data in the subject in dependence on the first and second parameters.
  • 11. The computer of claim 10, wherein the processor and the memory are sized and configured to allow the computer to be easily carried by the subject.
  • 12. A portable monitoring system for assessing respiratory data in a subject monitored during exercise with a physiological monitoring system, wherein the physiological monitoring system comprises a magnetometer for collecting respiratory data, the portable monitoring system comprising: a wearable item comprising one or more sensors that provide data comprising sizes at one or more selected positions on the subject's torso, the selected positions including one or more positions on the rib cage and one or more positions on the abdomen, the selected positions being selected so that the torso sizes change with respiration;a portable data unit operably linked to the sensors, the portable data unit comprising a processing device and a computer memory operably linked to the processing device and configured with computer instructions that cause the processor to perform the steps of:determining a tidal volume of the subject based on the respiratory data;determining a first parameter indicative of the relative contribution of expansion and contraction of the subject's rib cage to the subject's tidal volume;determining a second parameter indicative of median cumulative changes in end-expiratory lung volume; andassessing respiratory data in the subject in dependence on the first and second parameters.
  • 13. The portable monitoring system of claim 12, wherein the wearable item is selected from the group consisting of a garment, a shirt, or a band.
  • 14. The portable monitoring system of claim 12, wherein the portable data unit is housed so as to be carried on the wearable item worn by the subject.
  • 15. The portable monitoring system of claim 12, wherein the sensors comprise one or more inductive plethysmographic sensors or one or more posture and/or activity sensors.
  • 16. The portable system of claim 12, wherein the portable data unit stores data on a removable computer-readable memory.
  • 17. The portable monitoring system of claim 12, wherein the portable data unit wirelessly transmits data to a remote computer.
  • 18. The portable monitoring system of claim 12, wherein the subject performs normal daily activities during the monitoring period.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. nonprovisional application Ser. No. 11/437,335, filed May 19, 2006, which claims the benefit of prior U.S. provisional application 60/682,876 filed May 20, 2005. The disclosures of U.S. application Ser. Nos. 11/437,335 and 60/682,876 are hereby incorporated by reference in their entirety.

US Referenced Citations (245)
Number Name Date Kind
3534727 Roman Oct 1970 A
3731184 Goldberg et al. May 1973 A
3874368 Asrican Apr 1975 A
3926177 Hardway, Jr. et al. Dec 1975 A
4016868 Allison Apr 1977 A
4033332 Hardway, Jr. et al. Jul 1977 A
4102331 Grayzel et al. Jul 1978 A
4258718 Goldman Mar 1981 A
4267845 Robertson, Jr. et al. May 1981 A
4289142 Kearns Sep 1981 A
4306567 Krasner Dec 1981 A
4308872 Watson et al. Jan 1982 A
4373534 Watson Feb 1983 A
4387722 Kearns Jun 1983 A
4433693 Hochstein Feb 1984 A
4446872 Marsoner et al. May 1984 A
4452252 Sackner Jun 1984 A
4456015 Sackner Jun 1984 A
4463764 Anderson et al. Aug 1984 A
4494553 Sciarra et al. Jan 1985 A
4537196 Phillipps Aug 1985 A
4545376 Beiter Oct 1985 A
4546777 Groch et al. Oct 1985 A
4548204 Groch et al. Oct 1985 A
4549552 Groch et al. Oct 1985 A
4572197 Moore et al. Feb 1986 A
4580572 Granek et al. Apr 1986 A
4648407 Sackner Mar 1987 A
4672975 Sirota Jun 1987 A
4753088 Harrison et al. Jun 1988 A
4777962 Watson et al. Oct 1988 A
4796639 Snow et al. Jan 1989 A
4800495 Smith Jan 1989 A
4807640 Watson Feb 1989 A
4815473 Watson et al. Mar 1989 A
4817625 Miles Apr 1989 A
4819752 Zelin Apr 1989 A
4834109 Watson May 1989 A
4860766 Sackner Aug 1989 A
4863265 Flower et al. Sep 1989 A
4867571 Frick et al. Sep 1989 A
4889131 Salem et al. Dec 1989 A
4909260 Salem et al. Mar 1990 A
4911167 Corenman et al. Mar 1990 A
4920969 Suzuki et al. May 1990 A
4928692 Goodman et al. May 1990 A
4934372 Corenman et al. Jun 1990 A
4955379 Hall Sep 1990 A
4960118 Pennock Oct 1990 A
4966155 Jackson Oct 1990 A
4972842 Korten et al. Nov 1990 A
4981139 Pfohl Jan 1991 A
4986277 Sackner Jan 1991 A
5007427 Suzuki et al. Apr 1991 A
5025791 Niwa Jun 1991 A
5036857 Semmlow et al. Aug 1991 A
5040540 Sackner Aug 1991 A
5074129 Matthew Dec 1991 A
5076801 Schroll Dec 1991 A
5099841 Heinonen et al. Mar 1992 A
5099855 Yount Mar 1992 A
5111817 Clark et al. May 1992 A
5131399 Sciarra Jul 1992 A
5143089 Alt Sep 1992 A
5159935 Sackner et al. Nov 1992 A
5173151 Namose Dec 1992 A
5178151 Sackner Jan 1993 A
5224479 Sekine Jul 1993 A
5241300 Buschmann Aug 1993 A
5271551 Roepke Dec 1993 A
5295490 Dodakian Mar 1994 A
5299120 Kaestle Mar 1994 A
5301678 Wilson et al. Apr 1994 A
5329932 Yount Jul 1994 A
5331968 Williams et al. Jul 1994 A
5333106 Lanpher et al. Jul 1994 A
5348008 Bornn et al. Sep 1994 A
5353793 Bornn et al. Oct 1994 A
5416961 Vinay May 1995 A
5447164 Shaya et al. Sep 1995 A
RE35122 Corenman et al. Dec 1995 E
5520192 Kitney et al. May 1996 A
5533511 Kaspari et al. Jul 1996 A
5535738 Estes et al. Jul 1996 A
5544661 Davies et al. Aug 1996 A
5564429 Bornn et al. Oct 1996 A
5577510 Chittum et al. Nov 1996 A
5582337 McPherson et al. Dec 1996 A
5584295 Muller et al. Dec 1996 A
5588425 Sackner et al. Dec 1996 A
5601088 Swanson et al. Feb 1997 A
5611085 Rasmussen Mar 1997 A
5617847 Howe Apr 1997 A
5694939 Cowlings Dec 1997 A
5718234 Warden et al. Feb 1998 A
5719950 Osten et al. Feb 1998 A
5720709 Schnall Feb 1998 A
5724025 Tavori Mar 1998 A
5749365 Magill May 1998 A
5820567 Mackie Oct 1998 A
5825293 Ahmed Oct 1998 A
5848027 Dotter Dec 1998 A
5882307 Wright et al. Mar 1999 A
5899855 Brown May 1999 A
5913830 Miles Jun 1999 A
5921920 Marshall et al. Jul 1999 A
5937854 Stenzler Aug 1999 A
5989193 Sullivan Nov 1999 A
5991922 Banks Nov 1999 A
6002952 Diab et al. Dec 1999 A
6015388 Sackner et al. Jan 2000 A
6018677 Vidrine et al. Jan 2000 A
6035154 Takahata et al. Mar 2000 A
6047203 Sackner et al. Apr 2000 A
6066093 Kelly et al. May 2000 A
6067462 Diab et al. May 2000 A
6068568 Kozakura et al. May 2000 A
6070098 Moore-Ede et al. May 2000 A
6120441 Griebel Sep 2000 A
6142953 Burton et al. Nov 2000 A
6145551 Jayaraman et al. Nov 2000 A
6179786 Young Jan 2001 B1
6198394 Jacobsen et al. Mar 2001 B1
6223072 Mika et al. Apr 2001 B1
6254551 Varis Jul 2001 B1
6261238 Gavriely Jul 2001 B1
6273859 Remmers et al. Aug 2001 B1
6287264 Hoffman Sep 2001 B1
6302844 Walker et al. Oct 2001 B1
6306088 Krausman et al. Oct 2001 B1
6341504 Istook Jan 2002 B1
6361501 Amano et al. Mar 2002 B1
6381482 Jayaraman et al. Apr 2002 B1
6413225 Sackner et al. Jul 2002 B1
6419636 Young et al. Jul 2002 B1
6436057 Goldsmith Aug 2002 B1
6443890 Schulze et al. Sep 2002 B1
6449504 Conley et al. Sep 2002 B1
6454719 Greenhut Sep 2002 B1
6461307 Kristbjarnarson et al. Oct 2002 B1
6463385 Fry Oct 2002 B1
6478736 Mault Nov 2002 B1
6483929 Murakami et al. Nov 2002 B1
6485431 Campbell Nov 2002 B1
6506153 Littek et al. Jan 2003 B1
6511424 Moore-Ede et al. Jan 2003 B1
6513532 Mault et al. Feb 2003 B2
6551252 Sackner et al. Apr 2003 B2
6579231 Phipps Jun 2003 B1
6604115 Gary et al. Aug 2003 B1
6633772 Ford et al. Oct 2003 B2
6647252 Smith et al. Nov 2003 B2
6656127 Ben-Oren et al. Dec 2003 B1
6687523 Jayaraman et al. Feb 2004 B1
6699194 Diab et al. Mar 2004 B1
6702752 Dekker Mar 2004 B2
6709402 Dekker Mar 2004 B2
6721594 Conley et al. Apr 2004 B2
6723055 Hoffman et al. Apr 2004 B2
6726636 Der Ghazarian et al. Apr 2004 B2
6727197 Wilson et al. Apr 2004 B1
6747561 Reeves Jun 2004 B1
6775389 Harrison et al. Aug 2004 B2
6783498 Sackner et al. Aug 2004 B2
6801916 Roberge et al. Oct 2004 B2
6817979 Nihtila Nov 2004 B2
6858006 MacCarter et al. Feb 2005 B2
6881192 Park Apr 2005 B1
6941775 Sharma Sep 2005 B2
6961448 Nichols et al. Nov 2005 B2
6970731 Jayaraman et al. Nov 2005 B1
6993378 Wiederhold et al. Jan 2006 B2
7001337 Dekker Feb 2006 B2
7073129 Robarts et al. Jul 2006 B1
7077810 Lange et al. Jul 2006 B2
7081095 Lynn et al. Jul 2006 B2
7082327 Houben Jul 2006 B2
7099714 Houben Aug 2006 B2
7104962 Lomask et al. Sep 2006 B2
7154398 Chen et al. Dec 2006 B2
7207948 Coyle Apr 2007 B2
7254516 Case, Jr. et al. Aug 2007 B2
7267652 Coyle et al. Sep 2007 B2
7319385 Ruha Jan 2008 B2
7559902 Ting et al. Jul 2009 B2
7604603 Sackner et al. Oct 2009 B2
7670295 Sackner et al. Mar 2010 B2
7727161 Coyle et al. Jun 2010 B2
7762953 Derchak et al. Jul 2010 B2
7809433 Keenan Oct 2010 B2
7878979 Derchak Feb 2011 B2
20020032386 Sackner et al. Mar 2002 A1
20020084130 Der Ghazarian et al. Jul 2002 A1
20020090667 Ratcliffe et al. Jul 2002 A1
20020123701 Eriksen Sep 2002 A1
20030100843 Hoffman May 2003 A1
20030135097 Wiederhold et al. Jul 2003 A1
20030135127 Sackner et al. Jul 2003 A1
20030185408 Causevic et al. Oct 2003 A1
20030187341 Sackner et al. Oct 2003 A1
20040010420 Rooks Jan 2004 A1
20040019289 Ross Jan 2004 A1
20040030224 Sotos et al. Feb 2004 A1
20040111040 Ni et al. Jun 2004 A1
20040117204 Mazar Jun 2004 A1
20040122334 Yamashiro Jun 2004 A1
20040143194 Kihara et al. Jul 2004 A1
20040204636 Diab et al. Oct 2004 A1
20040210147 Houben Oct 2004 A1
20040225227 Newman Nov 2004 A1
20040249299 Cobb Dec 2004 A1
20050027207 Westbrook et al. Feb 2005 A1
20050054941 Ting et al. Mar 2005 A1
20050076908 Lee et al. Apr 2005 A1
20050119586 Coyle et al. Jun 2005 A1
20050125970 Nolan Jun 2005 A1
20050211247 Noda et al. Sep 2005 A1
20050228234 Yang Oct 2005 A1
20050240087 Keenan et al. Oct 2005 A1
20050256385 Diab et al. Nov 2005 A1
20060000420 Davies et al. Jan 2006 A1
20060036183 Sackner et al. Feb 2006 A1
20060074334 Coyle Apr 2006 A1
20060122528 Gal Jun 2006 A1
20060178591 Hempfling Aug 2006 A1
20060258914 Derchak et al. Nov 2006 A1
20060293609 Stahmann et al. Dec 2006 A1
20070027368 Collins et al. Feb 2007 A1
20070050715 Behar Mar 2007 A1
20070100622 Tavares May 2007 A1
20070150006 Libbus et al. Jun 2007 A1
20070177770 Derchak et al. Aug 2007 A1
20070208262 Kovacs Sep 2007 A1
20070209669 Derchak Sep 2007 A1
20070270671 Gal Nov 2007 A1
20080015454 Gal Jan 2008 A1
20080027341 Sackner et al. Jan 2008 A1
20080045815 Derchak et al. Feb 2008 A1
20080051839 Libbus et al. Feb 2008 A1
20080082018 Sackner et al. Apr 2008 A1
20080221401 Derchak et al. Sep 2008 A1
20080269644 Ray Oct 2008 A1
20090131759 Sims et al. May 2009 A1
20100274100 Behar et al. Oct 2010 A1
20110009766 McCool Jan 2011 A1
Foreign Referenced Citations (29)
Number Date Country
4214263 Nov 1993 DE
0262778 Apr 1988 EP
0875199 Nov 1998 EP
1596298 Aug 1981 GB
2116725 Sep 1983 GB
53126786 Jun 1978 JP
58109031 Jun 1983 JP
6337933 Feb 1988 JP
1091834 Apr 1989 JP
5168602 Jul 1993 JP
5298589 Nov 1993 JP
227383 Aug 1995 JP
516253 Sep 1998 JP
2001104259 Apr 2001 JP
WO9810699 Mar 1998 WO
WO0128420 Apr 2001 WO
WO0176467 Oct 2001 WO
WO02060370 Aug 2002 WO
WO02069878 Dec 2002 WO
WO03022149 Mar 2003 WO
WO2004019503 Mar 2004 WO
WO2005115242 Dec 2005 WO
WO2006002338 Jan 2006 WO
WO2006009830 Jan 2006 WO
WO2007089751 Feb 2007 WO
WO2007069111 Jun 2007 WO
WO2007089751 Aug 2007 WO
WO2009074973 Jun 2009 WO
WO2010027515 Mar 2010 WO
Non-Patent Literature Citations (76)
Entry
6th Portuguese Conference on Biomedical Engineering, “BioEng' 2001 Conference Papers”, (Jun. 2001) 6 pages.
Aliverti, et al., “Chronic Obstructive Pulmonary Disease: Regional Chest Wall Volumes During Exercise in Chronic Obstructive Pulmonary Disease.” Thorax, 59:210-216, 7 pages, 2004.
Almeida et al., “Wavelet Transform Based Matlab System for the Detection and Delineation of QRS Complexes in Ambulatory ECG Recordingd”, 6th Portuguese Conference on Biomedical Engineering (Jun. 2001), 2 pages.
Anderer et al., “Artifact Processing in Computerized Analysis of Sleep EEG—A Review” Neuropsychobiology, 40:150-157 (1999), 8 pages.
Bianchi et al., “Extraction of the Respiration Influence From the Heart Rate Variability Signal by Means of Lattice Adaptive Filter”, IEEE Transactions on Biomedical Engineering, pp. 121-122 (1994), 2 pages.
National Biometric Test Center, “The Functions of Biometric Identification Devices”, San Jose State University Biometrics Publications, www.engr.sjsu.edu/biometrics/publications—tech.html (printed Jul. 28, 2005), 25 pages.
National Biometric Test Center, “Biometric Technology—Testing, Evaluation, Results”, San Jose State University Biometrics Publications, www.engr.sjsu.edu/biometrics/publications—tech.html (printed Jul. 28, 2005), 13 pages.
Blechert et al., “Identifying Anxiety States Using Broad Sampling and Advance Processing of Peripheral Physiological Information,” Psychosom Med Dec. 2007; 935-43 Epub Nov. 8, 2007, 6 pages.
Bloch et al., “Specific respiratory patterns distinguish among human basic emotions,” International Journal of Psychophysiology, 11:141-154 (1991), 14 pages.
Bonnet et al., “EEG Arousals: Scoring Rules and Examples, A Preliminary Report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Assocation,” Sleep, 152(2): 173-184 (1992), 12 pages.
Brack, “Cheyne-Stokes respiration in patients with congestive heart failure,” Swiss Med Weekly 133:605-610 (2003), 7 pages.
Costa et al., “Multiscale Entropy Analysis of Complex Physiologic Time Series,” Physical Review Letters 89(6):068102-1-4 Aug. 5, 2002, 4 pages.
Coyle et al., “Home Measurement of Cough Indicates Circadian Frequency Pattern and Abnormal Distribution During Sleep,” LifeShirt System, study sponsored by Pfizer, Inc., Jun. 2004, 1 page.
Fahrenberg, “Origins and Developments of Ambulatory Monitoring and Assessment,” (2001), 30 pages.
Gore Electronic Products, “Expanded PTFE Insulation Material”, www.goreelectronics.com (visited Aug. 2005), 4 pages.
Grossman et al., “Reliability of Respiratory Tidal Volume Estimation by Means of Ambulatory Inductive Plethysmography,” Biomed Sci Instrum 42:193-8 (2006), 6 pages.
Grossman et al., “A Comparison of Three Quantification Methods for Estimation of Respiratory Sinus Arrhythmia”, Psychophycology, 27(6):702-714 (1900), 17 pages.
Istepanian et al., “Microcontroller-Based Underwater Acoustic ECG Telemetry System”, IEEE Transactions on Information Technology in Biomedicine, 1(2):150-154 (Jun. 1997), 5 pages.
Keenan et al., “Adaptive Filtering of Heart Rate Signals for an Improved Measure of Sympathovagal Balance,” Jan. 1, 2005, 8 pages.
Klabunde, “Electrocardiogram (EKG, ECG)”, Cardiovasular Physiology Concepts, www.cvphysiology.com (visited Mar. 2005),3 pages.
Lake et al., “Sample entropy analysis of neonatal heart rate variability,” Am J Physiol Regul Integr Comp 283:R789-97 (2002), 10 pages.
Marin et al., “Inspiratory Capacity, Dynamic Hyperinflation, Breathlessness, and Exercise Performance During the 6-Minute-Walk Test in Chronic Obstructive Pulmonary Disease”, Am. J. Respir. Crit. Care Med., vol. 163., pp. 1395-1399, (2001), 5 pages.
McCool et al., “Estimates of ventilation from body surface measurements in unstricted subjects,” J. Appl. Physiol. 61(3):1114-9 (1986), 6 pages.
McCool et al., “Tidal Volume and Respiratory Timing Derived From a Portable Ventilation Monitor,” Chest 122:684-91 (2002), 10 pages.
McNaughton et al., “Metallized Polymer Fibers as Leadwires and Intrafascicular Microelectrodes”, J. Neurosci. Methods, 70(1):103-10 (1996), 2 pages.
Micro-Coax, “About Micro-Coax”, www.micro-coax.com (visited Aug. 2004), 9 pages.
Niskanen et al., “Software for Advanced HRV Analysis”, University of Kuopio Department of Applied Physics Report Series, pp. 1-11 (Feb. 2002), 12 pages.
O'Donnell, “Ventilatory Limitations in Chronic Obstructive Pulmonary Disease”, Medicine & Science in Sports & Exercise, pp. S647-S655, (2001), 9 pages.
O'Donnell et al., “Dynamic Hyperinflation and Exercise Intolerance in Chronic Obstructive Pulmonary Disease”, Am. J. Respir. Crit. Care Med., 164:770-777 (2001), 8 pages.
Park et al., “Automated Detection and Elimination of Periodic ECG Artifacts in EEG Using the Energy Interval Histogram Method”, IEEE Transactions on Biomedical Engineering 49(12):1526-1533 (2002),8 pages.
Pietraszek et al., “Simple Telemetry System for ECG Recording”, Polish J. Med. Phys. & Eng. 2002; 8(3): 193-198, 4 pages.
Rampil, “A Primer for EEG Signal Processing in Anesthesia,” Anesthesiology 89(4):980-1002 Oct. 1998, 15 pages.
Richman et al., “Physiological time-series analysis using approximate entropy and sample entropy,” Am. J. Physiol Circ Physiol 278:H2039-49 (2000), 11 pages.
Signal Consulting Inc., “Inductance of Circular Loop”, www.sigcon.com (visited Aug. 2005), 2 pages.
Sijbers et al., “Reduction of ECG and gradient related artifacts in simultaneously recorded human EEG/MRI data,”, Magnetic Resonance Imaging 18:881-6 (2000), 6 pages.
Snyder et al., “Ventilatory Responses to Hypoxia and High Altitude During Sleep in Aconcagua Climbers,” Wilderness and Environmental Medicine 18:138-145 (2007), 8 pages.
Szabo et al., “Prognostic Value of Heart Rate Variability in Chronic Congestive Heart Failure Secondary to Idiopathic or Ischemic Dilated Cardiomypathy,” Am J Cardiol. 79:978-980 (1997), 3 pages.
van Dijk et al., “Determinants of Brachial Artery mean 24 h PulsePressure in Individuals with Type II diabetes mellitus and untreated mild hypertension”, Clinical Science (2002), 102, pp. 177-186, 10 pages.
Vogiatzis, et al., “Respiratory Kinematics by Optoelectronic Plethysmography During Exercise in Men and Women.”, Eur J of App Physiol, 581-587, 7 pages, 2004, 7 pages.
Wachowski, Andy and Larry, The Matrix, released Mar. 31, 1999 by Warner Bros. Pictures, see 1:26:29, 2:03:10, and 2:04:41, 13 pages.
Wilhelm et al., “Distinguishing Emotional From Physical Activation in Ambulatory Psychophysiological Monitoring,” Biomed Sci Instrum 42:458-63 (2006), 6 pages.
Wilhelm et al., “Taking the laboratory to the skies: Ambulatory assessment of self-report, autonomic, and respiratory responses in flying phobia,” Psychophysiology 35:596-606 (1998), 11 pages.
Supplementary Partial European Search Report of the European Patent Office, Application No. EP 06784447.2, dated Jan. 20, 2010, 9 pages.
Supplementary Partial European Search Report of the European Patent Office, Application No. EP 04759405.6, dated Jan. 25, 2011, 4 pages.
International Search Report and the Written Opinion of the International Searching Authority, application No. PCT/US2008/061171, dated Nov. 14, 2008, 10 pages.
International Search Report and the Written Opinion of the International Searching Authority, application No. PCT/US06/60264, dated Jan. 15, 2008, 8 pages.
International Search Report and the Written Opinion of the International Searching Authority, application No. PCT/US2007/82688, dated May 8, 2008, 7 pages.
International Search Report and the Written Opinion of the International Searching Authority, application No. PCT/US2008/072414, dated Nov. 12, 2008, 7 pages.
Extended European Search Report for Application No. EP 07798146.2, Applicant: adidas AG, mailed Oct. 19, 2010.
Extended European Search Report for Application No. EP 10174873.9, Applicant: adidas AG, mailed Dec. 8, 2010.
Extended European Search Report for Application No. EP 10174680.8, Applicant: adidas AG, mailed Dec. 9, 2010.
Extended European Search Report for Application No. EP 10174876.2, Applicant: adidas AG, mailed Dec. 9, 2010.
Extended European Search Report for Application No. EP 10174881.2, Applicant: adidas AG, mailed Dec. 9, 2010.
Extended European Search Report for Application No. EP 10174683.2, Applicant: adidas AG, mailed Dec. 27, 2010.
Partial European Search Report for Application No. EP 10174885.3, Applicant: adidas AG, mailed Jan. 4, 2011.
Office Action dated Nov. 30, 2010 from Japanese Appl. No. 2006-509897, Adidas AG, Systems and Methods for Respiratory Event Detection, with translation.
Office Action dated Aug. 2, 2010 from U.S. Appl. No. 11/373,822, Sackner, System and Methods for Ambulatory Monitoring of Physiological Signs, filed Mar. 9, 2006.
Office Action dated Sep. 28, 2010 from U.S. Appl. No. 11/503,350, Behar, Systems and Methods for Monitoring Subjects in Potential Physiological Distress, Aug. 10, 2006.
Office Action dated Oct. 15, 2010 from U.S. Appl. No. 11/627,198, Derchak, System and Method for Identity Confirmation Using Physiologic Biometrics to Deteimine a Physiologic Fingerprint, filed Jan. 25, 2007.
Office Action dated Nov. 18, 2010 from U.S. Appl. No. 11/492,484, Behar, Computer Interfaces Including Physiologically Guided Avatars, filed Jul. 24, 2006.
Office Action dated Jan. 4, 2011 from U.S. Appl. No. 11/233,317,Gal, Improved Sensors for Inductive Plethysmographic Monitoring Applications and Apparel Using Same, Sep. 21, 2005.
Office Action dated Jan. 27, 2011 from U.S. Appl. No. 10/991,877, Keenan, Method and system for processing data from ambulatory physiological monitoring, Nov. 18, 2004.
Office Action dated Feb. 2, 2011 from U.S. Appl. No. 11/373,822, Sackner, Systems and methods for ambulatory monitoring of physiological signs, Mar. 9, 2006.
U.S. Appl. No. 13/357,772, Sackner, System and Methods for Ambulatory Monitoring of Physiological Signs, filed Feb. 17, 2006.
U.S. Appl. No. 11/373,822, Sackner, System and Methods for Ambulatory Monitoring of Physiological Signs, filed Mar. 9, 2006.
U.S. Appl. No. 12/869,576, Stone, Method and System for Limiting Interference in Magnetometer Fields, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,578, Derchak, Noninvasive Method and System for Monitoring Physiological Characterisitics, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,582, Derchak, Noninvasive Method and System for Monitoring Physiological Characteristics and Athletic Performance, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,585, Derchak, Noninvasive Method and System for Monitoring Physiological and Athletic Performance Characteristics of a Subject, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,586, Derchak, Physiological Database and System for Population Modeling and Method of Population Modeling, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,592, Derchak, Multimodal Method and System for Transmitting Information About a Subject, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,625, Derchak, Method and System for Interpretation and Analysis of Physiological, Performance, and Contextual Information, filed Aug. 26, 2010.
U.S. Appl. No. 12/869,627, Derchak, Physiological Monitoring Garment, filed Aug. 26, 2010.
U.S. Appl. No. 12/872,174, Derchak, Physiological Monitoring Garment, filed Aug. 31, 2010.
U.S. Appl. No. 12/971,193, Sackner, Systems and Methods for Ambulaory Monitoring of Physiological Signs, filed Dec. 17, 2010.
U.S. Appl. No. 12/976,080, Derchak, Methods and Systems for Monitoring Respiratory Data, filed Dec. 22, 2010.
Related Publications (1)
Number Date Country
20110092795 A1 Apr 2011 US
Provisional Applications (1)
Number Date Country
60682876 May 2005 US
Continuations (1)
Number Date Country
Parent 11437335 May 2006 US
Child 12976080 US